Apellis Pharmaceuticals, Inc.
APLS
Rang în acțiuni
#3328
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Preț acțiune
$41.03
Ultima sincronizare: 2026-05-15
Capitalizare de piață
$5.25B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
44.93%
Țară
US
Tranzacționează Apellis Pharmaceuticals, Inc. (APLS)
Categorie
Healthcare
Venituri pentru Apellis Pharmaceuticals, Inc. (APLS)
Venituri în Mar 2026 TTM: $1.11B
Conform celor mai recente rapoarte financiare ale Apellis Pharmaceuticals, Inc., venitul actual al companiei (TTM) este $1.11B. În anul 2023, compania a avut un venit de $396.59M o creștere față de venitul din anul 2022, care a fost de $75.42M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Apellis Pharmaceuticals, Inc. din 2013 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $1.11B | 41.45% |
| 2024 | $781.37M | 97.02% |
| 2023 | $396.59M | 425.83% |
| 2022 | $75.42M | 13.31% |
| 2021 | $66.56M | -73.44% |
| 2020 | $250.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 1,042.18% |
US
|
|
| $2.23B | 101.58% |
US
|
|
| $15.74B | 1,324.47% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 444.77% |
NL
|
